NCT05237206
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 90 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known central nervous system (CNS) metastases and/or leptomeningeal disease
https://ClinicalTrials.gov/show/NCT05237206